SNDX-5613, a potent and specific Menin-MLL inhibitor, will be tested in phase I clinical trial in patients with relapsed or refractory MLL-r acute leukemias harboring or mutations in Nucleophosmin 1 (NPM1) gene (NCT04065399). This evidence concerns the gene NPM1 and acute leukemia.